MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, announces the closing of the ExoDx business acquisition from Bio-Techne Corporation, which includes the ExoDx Prostate test. Total consideration for the acquisition is $15 million, with $5 million in stock paid at closing and $2.5 million to be paid annually over the following 4 years with 50% in cash and 50% in cash or stock at mdxhealth’s discretion. Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment.
Read the full article: MDxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne //
Source: https://www.globenewswire.com/news-release/2025/09/15/3150431/0/en/Mdxhealth-Announces-Closing-of-Exosome-Diagnostics-Acquisition-from-Bio-Techne.html